These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 35177298)

  • 1. Relation of fever intensity and antipyretic use with specific antibody response after two doses of the BNT162b2 mRNA vaccine.
    Tani N; Chong Y; Kurata Y; Gondo K; Oishi R; Goto T; Minami J; Onozawa K; Nagano S; Shimono N; Ikematsu H; Kuwano H
    Vaccine; 2022 Mar; 40(13):2062-2067. PubMed ID: 35177298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of Postvaccination Fever With Specific Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 BNT162b2 Booster and No Significant Influence of Antipyretic Medication.
    Tani N; Ikematsu H; Goto T; Gondo K; Inoue T; Yanagihara Y; Kurata Y; Oishi R; Minami J; Onozawa K; Nagano S; Kuwano H; Akashi K; Shimono N; Chong Y
    Open Forum Infect Dis; 2022 Oct; 9(10):ofac493. PubMed ID: 36267253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine.
    Kobashi Y; Shimazu Y; Kawamura T; Nishikawa Y; Omata F; Kaneko Y; Kodama T; Tsubokura M
    PLoS One; 2022; 17(6):e0269917. PubMed ID: 35687563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between use of antipyretics and antibody titers after two doses of the BNT162b2 SARS-CoV-2 vaccine in adolescents and young adults with underlying diseases.
    Aiba H; Funaki T; Yamada M; Miyake K; Ueno S; Tao C; Myojin S; Matsui T; Ogimi C; Kato H; Miyairi I; Shoji K
    J Infect Chemother; 2024 Feb; 30(2):176-178. PubMed ID: 37769991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association between antipyretic analgesics use and SARS-CoV-2 antibody titers following the second dose of the BNT162b2 mRNA vaccine: An observational study.
    Inoue Y; Li Y; Yamamoto S; Fukunaga A; Ishiwari H; Ishii M; Miyo K; Ujiie M; Sugiura W; Ohmagari N; Mizoue T
    Vaccine; 2023 Nov; 41(49):7317-7321. PubMed ID: 37945490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Young age, female sex, and presence of systemic adverse reactions are associated with high post-vaccination antibody titer after two doses of BNT162b2 mRNA SARS-CoV-2 vaccination: An observational study of 646 Japanese healthcare workers and university staff.
    Uwamino Y; Kurafuji T; Sato Y; Tomita Y; Shibata A; Tanabe A; Yatabe Y; Noguchi M; Arai T; Ohno A; Yokota H; Yamasawa W; Uno S; Nishimura T; Hasegawa N; Saya H; Wakui M; Murata M;
    Vaccine; 2022 Feb; 40(7):1019-1025. PubMed ID: 35033389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of prior infection status on antibody response to the BNT162b2 mRNA COVID-19 vaccine in healthcare workers at a COVID-19 referral hospital in Milan, Italy.
    Milazzo L; Pezzati L; Oreni L; Kullmann C; Lai A; Gabrieli A; Bestetti G; Beschi C; Conti F; Ottomano C; Gervasoni C; Meroni L; Galli M; Antinori S; Ridolfo AL
    Hum Vaccin Immunother; 2021 Dec; 17(12):4747-4754. PubMed ID: 35086438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine.
    Yamamoto S; Fukunaga A; Tanaka A; Takeuchi JS; Inoue Y; Kimura M; Maeda K; Ueda G; Mizoue T; Ujiie M; Sugiura W; Ohmagari N
    Vaccine; 2022 Mar; 40(13):1924-1927. PubMed ID: 35183384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody Responses to the BNT162b2 mRNA Vaccine in Healthcare Workers in a General Hospital in Japan: A Comparison of Two Assays for Anti-spike Protein Immunoglobulin G.
    Hibino M; Watanabe S; Kamada R; Tobe S; Maeda K; Horiuchi S; Kondo T
    Intern Med; 2022 Mar; 61(6):811-819. PubMed ID: 34980798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine.
    Yavuz E; Günal Ö; Başbulut E; Şen A
    J Med Virol; 2022 Aug; 94(8):3768-3775. PubMed ID: 35434796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinations.
    Cheng A; Hsieh MJ; Chang SY; Ieong SM; Cheng CY; Sheng WH; Chang SC
    J Formos Med Assoc; 2023 May; 122(5):384-392. PubMed ID: 36564299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
    Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
    Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No significant influence of pre-vaccination antipyretic use on specific antibody response to a BNT162b2 vaccine booster against COVID-19.
    Tani N; Ikematsu H; Goto T; Gondo K; Yanagihara Y; Kurata Y; Oishi R; Minami J; Onozawa K; Nagano S; Kuwano H; Akashi K; Shimono N; Chong Y
    Vaccine X; 2022 Dec; 12():100224. PubMed ID: 36213591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamics of Antibody Response to BNT162b2 mRNA COVID-19 Vaccine: A 7-Month Follow-Up Study.
    Olariu TR; Ursoniu S; Marincu I; Lupu MA
    Medicina (Kaunas); 2021 Dec; 57(12):. PubMed ID: 34946275
    [No Abstract]   [Full Text] [Related]  

  • 17. Demographic and Clinical Factors Associated With Anti-SARS-CoV-2 Antibody Levels After 2 BNT162b2 mRNA Vaccine Doses.
    Nam SY; Jeon SW; Lee HS; Lim HJ; Lee DW; Yoo SS
    JAMA Netw Open; 2022 May; 5(5):e2212996. PubMed ID: 35587345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients.
    Higashimoto Y; Kozawa K; Miura H; Kawamura Y; Ihira M; Hiramatsu H; Suzuki R; Haga K; Takai-Todaka R; Sawada A; Katayama K; Yoshikawa T
    Hum Vaccin Immunother; 2022 Nov; 18(6):2105611. PubMed ID: 36094467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.
    Furukawa K; Tjan LH; Kurahashi Y; Sutandhio S; Nishimura M; Arii J; Mori Y
    JAMA Netw Open; 2022 May; 5(5):e2210780. PubMed ID: 35532938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines.
    Zhang R; Leung KY; Liu D; Fan Y; Lu L; Chan PC; To KK; Chen H; Yuen KY; Chan KH; Hung IF
    mSphere; 2022 Apr; 7(2):e0091521. PubMed ID: 35285250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.